Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Micro cap

Gujarat Inject (Kerala) posts 7x revenue jump in Q4, flips to profit

Q4 revenue surged to ₹30.7 cr from ₹4.2 cr a year earlier; net profit of ₹1.64 cr reverses losses. Capital work-in-progress of ₹20.8 cr signals a major expansion phase.

5 earlier stories on Gujarat Inject (Kerala) Ltd.
Mkt cap₹180 cr
P/E99.23×
ROE0.97%
Debt / eq.0.00
₹30.7 cr Q4 revenue, up 7x YoY from ₹4.2 cr

What's new

  • Q4 revenue surged to ₹30.7 cr from ₹1.6 cr in preceding quarter and ₹4.2 cr a year ago.
  • Net profit of ₹1.64 cr in Q4, reversing recent losses.
  • Balance sheet shows ₹20.8 cr in capital work-in-progress, hinting at major expansion.

Why this matters

For a nano-cap, this is a material inflection point. The scale of the turnaround suggests either a large new contract or a fundamental business shift. The CWIP of ₹20.8 cr relative to full-year revenue of ₹36.3 cr means the company is investing heavily for future capacity—capital expenditure is outpacing current operations.

What we're watching

  • Whether the revenue spike is sustainable or a one-off.
  • Progress on the capital work-in-progress converting to revenue-generating assets.
  • FY27 guidance or any management commentary; cash flow and debt levels given the expansion.

The full read

Gujarat Inject (Kerala) moved from near-zero revenue to ₹30.7 cr in a single quarter, propelling full-year revenue to ₹36.3 cr—almost double the prior year. Profitability returned with a net profit of ₹1.64 cr in Q4, reversing recent losses. More tellingly, the balance sheet now carries ₹20.8 cr in capital work-in-progress, a figure that represents more than half of the year's total revenue. This suggests the company is not just enjoying a one-off bump but actively expanding capacity—a rare move for a nano-cap. The open question is sustainability: can the company maintain this run rate, and how will it fund the expansion? The next quarterly numbers will be the real test.

Mentioned: Gujarat Inject (Kerala) Ltd · ₹20.8 cr CWIP · Q4 FY26
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Gujarat Inject (Kerala) Ltd.

Pharmaceuticals
₹192 cr
P/E 105.61×

Latest quarter · Mar 2026

Sales₹31 cr
Net profit₹2 cr
Op. margin+7.4%
EPS₹1.12

Strength & growth

Debt / equity0.00×
Current ratio40.77×
  1. 20 May 2026 · 7:06 PM IST Gujarat Inject (Kerala) posts 7x revenue jump in Q4, flips to profit
  2. 4d ago Gujarat Inject fills top post after chairman's death, but new MD is from plastics
  3. 16d ago Gujarat Inject loses Chairman, CFO & Whole-Time Director in single death
  4. 29d ago Gujarat Inject lands ₹14.49 cr solar order, nearly 40% of annual revenue
  5. 32d ago Gujarat Inject wins ₹1.07 cr solar module order from Ottire Lifestyle